BMT CTN PROTOCOL 1302, Multicenter Phase II, Double Blind, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma

Type of Cancer
Multiple Myeloma

Phase

Division (Location)

Study ID

NCT#

Brief Description
BMT CTN PROTOCOL 1302, Multicenter Phase II, Double Blind, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.